Avinger-healthcare_professionals-hero-mobile Avinger-healthcare_professionals-hero-tablet
healthcare_professionals

Your decisions today help build the future

banner-img07

Healthcare Professionals

Lumivascular technology is radically changing the way vascular disease is treated. Through the CONNECT II and VISION trial, we were able to receive FDA clearance on both our CTO crossing catheter (Ocelot) and atherectomy catheter (Pantheris). Being able to see inside the artery with Optical Coherence Tomography (OCT) while performing the procedure is a real game changer. It allows the operator to make informed decisions for long term results while leaving normal arterial layers behind.

See Case Studies

Clinical trials prove safety.

Gathering information through seeing inside the artery while performing the procedure may allow for better long term outcomes when you don’t disturb healthy layers of the artery. The data below shows the importance of visualization inside the artery.

Pantheris VISION IDE Trial

  • 130 Patients
  • 20 Sites
  • 164 Lesions

The VISION Trial is a multi-center, non randomized global clinical study designed to evaluate the safety and efficacy of Pantheris, the first-ever image-guided atherectomy device for use in Lumivascular procedures using real-time intravascular visualization technology called Optical Coherence Tomography, or OCT.

TLR 6 Months
8%
6 month target lesion revascularization (TLR by patient)

7.3 ± 4.1cm mean lesion length
SFA-Popliteal lesion location

Dissections
Perforations
No Adventitia
1% Adventitia

Total Luminal Gain 72%

  • Pre-stenosis
    79%
  • PANTHERIS STANDALONE
    30%
  • PANTHERIS +/- adjunctive therapy
    22%

Ocelot Connect II Trial

  • 100 Patients
  • 14 Sites

The CONNECT II study was a prospective, multicenter, non-randomized single-arm study of the safety and effectiveness of the Ocelot catheter in CTO crossing. Key inclusion criteria were a 99% to 100% stenosed femoropopliteal segment, lesion length between 1 and 30 cm, and resistance to guidewire crossing.

166mm mean lesion length
SFA lesion location

Efficacy
Safety

Luminal crossing

93%
7%
TRUE LUMEN SUBINTiMAL
banner-img06

Case Studies

View cases performed by your peers and colleagues in lesions below the knee, above the knee, CTOs, and more. These cases help show how Ocelot and Pantheris are changing the way operators see and perform procedures.

view case studies

Events with Avinger

Visit Avinger at the following upcoming events to learn more on how Lumivascular is radically changing the way vascular disease is treated.

IMAGINE

Scottsdale, AZ
  • November 17-18, 2016
  • Hosted by John B. Simpson PhD MD

LINC

Leipzig, Germany
  • January 24-27, 2017
  • Booth #000
  • Frank J. Veith MD
  • Arnie Schwindt MD
  • Ali F. AbuRahma, MD
Past events